This is a developing story. Please check back for updates. | After a tumultuous tenure marked by recent clashes with the ...

In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy ...

Flagship Pioneering-backed Alltrna is once again laying off staff, this time reducing its workforce by 19 people. | Flagship ...

After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...

The FDA will end a roughly nine-month hiatus of drug-related advisory committee meetings, with plans to convene its first session of 2026 to scrutinize a pair of oncology applications from AstraZen | ...

Zealand Pharma’s Roche-partnered amylin analog demonstrated “placebo-like tolerability” and up to 10.7% mean weight loss at ...

Two weeks after Teva touted promising long-term data for its Sanofi-partnered bowel disease drug, the Israeli pharma ...

Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while ...

United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial ...

With colon cancer deaths rising among younger adults and millions of eligible Americans skipping their colonoscopies, Guardant Health is taking its Shield blood test on the road in hopes of tackling ...

T-cell engager (TCE) specialist Candid Therapeutics has entered into a reverse merger agreement with Rallybio that will allow ...

The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.